<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27663742</article-id>
<article-id pub-id-type="pmc">5068319</article-id>
<article-id pub-id-type="publisher-id">201610812</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1610812113</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>PNAS Plus</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Neuroscience</subject>
</subj-group>
</subj-group>
<series-title>PNAS Plus</series-title>
</article-categories>
<title-group>
<article-title>Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice</article-title>
<alt-title alt-title-type="short">Elevated ERK-p90RSK activity in fragile X mice</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sawicka</surname>
<given-names>Kirsty</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pyronneau</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chao</surname>
<given-names>Miranda</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bennett</surname>
<given-names>Michael V. L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zukin</surname>
<given-names>R. Suzanne</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>3</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Dominick P. Purpura Department of Neuroscience, <institution>Albert Einstein College of Medicine</institution>, New York, <addr-line>NY</addr-line> 10461</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>3</sup>To whom correspondence may be addressed. Email: <email>ksawicka@rockefeller.edu</email>, <email>suzanne.zukin@einstein.yu.edu</email>, or <email>michael.bennett@einstein.yu.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Contributed by Michael V. L. Bennett, August 8, 2016 (sent for review June 24, 2016; reviewed by Leonard K. Kaczmarek and Siqiong June Liu)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: K.S., A.P., M.V.L.B., and R.S.Z. conceived and designed research; K.S., A.P., and M.C., performed research, collected and assembled the data; K.S., A.P., M.C., M.V.L.B., and R.S.Z. analyzed and interpreted data; and K.S., A.P., M.C., M.V.L.B., and R.S.Z. wrote and approved the final manuscript.</p>
</fn>
<fn fn-type="con">
<p>Reviewers: L.K.K., Yale University School of Medicine; and S.J.L., Louisiana State University Health Sciences Center.</p>
</fn>
<fn fn-type="equal" id="fn1">
<p><sup>1</sup>K.S. and A.P. contributed equally to this work.</p>
</fn>
<fn fn-type="present-address" id="fn2">
<p><sup>2</sup>Present address: Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, NY 10065.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>11</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>9</month>
<year>2016</year>
</pub-date>
<volume>113</volume>
<issue>41</issue>
<fpage>E6290</fpage>
<lpage>E6297</lpage>
<permissions></permissions>
<self-uri xlink:href="pnas.201610812.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Fragile X syndrome is the most common heritable cause of intellectual disability and autism. Elevated protein synthesis is considered a major contributor to the pathophysiology of fragile X. ERK (extracellular signal-regulated kinase) and mTOR (mechanistic target of rapamycin) are key signaling molecules in two prominent pathways that regulate protein synthesis. A major finding of this study is that ERK (but not mTOR) signaling is elevated in the neocortex of fragile X mice. Elevated ERK activity causes overactivation of p90-ribosomal S6 kinase (RSK) and hyperphosphorylation of ribosomal protein S6. Audiogenic seizures in fragile X mice, which mimic sensory hypersensitivity in fragile X humans, are prevented by RSK inhibition. Thus, RSK is a potential therapeutic target for treatment of fragile X.</p>
</abstract>
<abstract>
<p>Fragile X syndrome (FXS) is the most common heritable cause of intellectual disability and a leading genetic form of autism. The <italic>Fmr1</italic> KO mouse, a model of FXS, exhibits elevated translation in the hippocampus and the cortex. ERK (extracellular signal-regulated kinase) and mTOR (mechanistic target of rapamycin) signaling regulate protein synthesis by activating downstream targets critical to translation initiation and elongation and are known to contribute to hippocampal defects in fragile X. Here we show that the effect of loss of fragile X mental retardation protein (FMRP) on these pathways is brain region specific. In contrast to the hippocampus, ERK (but not mTOR) signaling is elevated in the neocortex of fragile X mice. Phosphorylation of ribosomal protein S6, typically a downstream target of mTOR, is elevated in the neocortex, despite normal mTOR activity. This is significant in that S6 phosphorylation facilitates translation, correlates with neuronal activation, and is altered in neurodevelopmental disorders. We show that in fragile X mice, S6 is regulated by ERK via the “alternative” S6 kinase p90-ribosomal S6 kinase (RSK), as evidenced by the site of elevated phosphorylation and the finding that ERK inhibition corrects elevated RSK and S6 activity. These findings indicate that signaling networks are altered in the neocortex of fragile X mice such that S6 phosphorylation receives aberrant input from ERK/RSK. Importantly, an RSK inhibitor reduces susceptibility to audiogenic seizures in fragile X mice. Our findings identify RSK as a therapeutic target for fragile X and suggest the therapeutic potential of drugs for the treatment of FXS may vary in a brain-region–specific manner.</p>
</abstract>
<kwd-group>
<kwd>intellectual disability</kwd>
<kwd>autism</kwd>
<kwd>mTOR</kwd>
<kwd>FMRP</kwd>
<kwd>RSK</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">HHS | NIH | National Institute of Mental Health (NIMH)<named-content content-type="funder-id">100000025</named-content></funding-source>
<award-id rid="sp1">MH092877</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">|NIH| National Institute of Neurological Diseases and Stroke</funding-source>
<award-id rid="sp2">NS045693</award-id>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">Evelyn F. McKnight Brain Research Foundation (McKnight Brain Research Foundation)<named-content content-type="funder-id">100007049</named-content></funding-source>
<award-id rid="sp3">N/A</award-id>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">NARSAD Distinguished Investigator Award</funding-source>
<award-id rid="sp4">N/A</award-id>
</award-group>
<award-group id="gs5">
<funding-source id="sp5">F. M. Kirby Foundation<named-content content-type="funder-id">100001205</named-content></funding-source>
<award-id rid="sp5">N/A</award-id>
</award-group>
<award-group id="gs6">
<funding-source id="sp6">FRAXA Research Foundation<named-content content-type="funder-id">100000297</named-content></funding-source>
<award-id rid="sp6">Postdoctoral fellowship to KS</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="8"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>